Connect Biopharma Holdings (CNTB) Asset Utilization Ratio (2025 - 2026)

Connect Biopharma Holdings (CNTB) posted quarterly Asset Utilization Ratio of 0.0 for Q1 2026, up 286.93% on a QoQ basis from 0.0 in Q4 2025.

Connect Biopharma Holdings (CNTB) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Connect Biopharma Holdings (CNTB) has reported Asset Utilization Ratio for 2 consecutive years, with 0.0 the latest figure, recorded in Q1 2026.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0 (changed N/A YoY) and the FY2025 annual result came in at 0.0, down 99.64% from the prior year.
Asset Utilization Ratio advanced to 0.0 in Q1 2026 per CNTB's latest filing, from 0.0 in the prior quarter.
Over the last five years, Asset Utilization Ratio for CNTB reached as high as 0.02 in Q2 2025 and fell as low as 0.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	0.69
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	0.37
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Connect Biopharma Holdings	120.44 Mn	120.44 Mn	-	0.00

Download Data